Recurrence Pattern and Proposed Surveillance Protocol Following Post-Chemotherapy Retroperitoneal Lymph Node Dissection

Journal of Urology

Volumn 177, Issue 1, 2007, Pages 131-138

  Spiess, Philippe E ^a   Brown, Gordon A ^a   Liu, Ping ^a   Tu, Shi Ming ^a   Tannir, Nizar M ^a   Evans, James G ^a   Kamat, Ashish M ^a   Kassouf, Wassim ^a   Pisters, Louis L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

adjuvant; chemotherapy; lymph node excision; recurrence; retroperitoneal space; testicular neoplasms

Indexed keywords

ALPHA FETOPROTEIN; BLEOMYCIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; VINBLASTINE;

ABDOMEN; ADULT; ARTICLE; BRAIN; CANCER PATIENT; DISEASE COURSE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LYMPH NODE; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NON SEMINOMATOUS GERMINOMA; POSTOPERATIVE CARE; PRACTICE GUIDELINE; PREOPERATIVE CARE; PRIORITY JOURNAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; SURGICAL PATIENT; TESTIS CANCER; THORAX; TREATMENT OUTCOME;

ADOLESCENT; ADULT; HUMANS; LYMPH NODE EXCISION; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GERM CELL AND EMBRYONAL; POPULATION SURVEILLANCE; RETROPERITONEAL SPACE; RETROSPECTIVE STUDIES; TESTICULAR NEOPLASMS;

EID: 33845332031     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2006.08.092     Document Type: Article

References (20)

1. Ries L.A.G., Eisner M.P., Kosary C.L., Hankey B.F., Miller B.A., Clegg L., et al. SEER Cancer Statistics Review, 1975-2002. Based on November 2004 SEER data submission, posted to the SEER website 2005 (2005), National Cancer Institute, Bethesda, MD
2. Stephenson A.J., Bosl G.J., Motzer R.J., Kattan M.W., Stasi J., Bajorin D.F., et al. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer. impact of patient selection factors on outcome. J Clin Oncol 23 (2005) 2781
3. Donohue J.P., Thornhill J.A., Foster R.S., Bihrle R., Rowland R.G., and Einhorn L.H. The role of retroperitoneal lymphadenectomy in clinical stage B testis cancer. the Indiana University experience (1965 to 1989). J Urol 153 (1995) 85
4. Logothetis C.J., Swanson D.A., Dexeus F., Chong C., Ogden S., Ayala A.G., et al. Primary chemotherapy for clinical stage II nonseminomatous germ cell tumors of the testis. follow-up of 50 patients. J Clin Oncol 5 (1987) 906
5. Sheinfeld J. The role of adjunctive postchemotherapy surgery for nonseminomatous germ-cell tumors. current concepts and controversies. Semin Urol Oncol 20 (2002) 262
6. Oldenburg J., Alfsen G.C., Lien H.H., Aass N., Waehre H., Fossa S.D., et al. Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses. J Clin Oncol 21 (2003) 3310
7. Donohue J.P. Evolution of retroperitoneal lymphadenectomy (RPLND) in the management of non-seminomatous testicular cancer (NSGCT). Urol Oncol 21 (2003) 129
8. Stenning S.P., Parkinson M.C., Fisher C., Mead G.M., Cook P.A., Fossa S.D., et al. Postchemotherapy residual masses in germ cell tumor patients. content, clinical features, and prognosis. Medical Research Council Testicular Tumour Working Party. Cancer 83 (1998) 1409
9. Levy D.A., Slaton J.W., Swanson D.A., and Dinney C.P. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol 159 (1998) 1163
10. Lam J.S., Shvarts O., Leppert J.T., Pantuck A.J., Figlin R.A., and Belldegrun A.S. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urol 174 (2005) 466
11. Kaplan E.L., and Meier E.P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457
12. Stephenson A.J., Chetner M.P., Rourke K., Gleave M.E., Signaevsky M., Palmer B., et al. Guidelines for the surveillance of localized renal cell carcinoma based on the patterns of relapse after nephrectomy. J Urol 172 (2004) 58
13. Baniel J., Foster R.S., Gonin R., Messemer J.E., Donohue J.P., and Einhorn L.H. Late relapse of testicular cancer. J Clin Oncol 13 (1995) 1170
14. Shahidi M., Norman A.R., Dearnaley D.P., Nicholls J., Horwich A., and Huddart R.A. Late recurrence in 1263 men with testicular germ cell tumors. Multivariate analysis of risk factors and implications for management. Cancer 95 (2002) 520
15. Dieckmann K.P., Albers P., Classen J., DeWit M., Pichlmeier U., Rick O., et al. Late relapse of testicular germ cell neoplasms. a descriptive analysis of 122 cases. J Urol 173 (2005) 824
16. Ronnen E.A., Kondagunta G.V., Bacik J., Marion S., Bajorin D.F., Sheinfeld J., et al. Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapy. J Clin Oncol 23 (2005) 6999
17. Travis L.B., Curtis R.E., Storm H., Hall P., Holowaty E., van Leeuwen F.E., et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 89 (1997) 1429
18. van Leeuwen F.E., Stiggelbout A.M., van den Belt-Dusebout A.W., Noyon R., Eliel M.R., van Kerkhoff E.H., et al. Second cancer risk following testicular cancer. a follow-up study of 1,909 patients. J Clin Oncol 11 (1993) 415
19. Travis L.B., Fossa S.D., Schonfeld S.J., McMaster M.L., Lynch C.F., Storm H., et al. Second cancers among 40,576 testicular cancer patients. focus on long-term survivors. J Natl Cancer Inst 97 (2005) 1354
20. Gerl A., and Schierl R. Urinary excretion of platinum in chemotherapy-treated long-term survivors of testicular cancer. Acta Oncol 39 (2000) 519